International Health Insurance

September 17, 2019
Global Reach Health

Erleada Receives New Indication

September 17, 2019 – The U.S. FDA has approved a new indication for Erleada® (apalutamide), manufactured by Janssen Pharmaceuticals. The product is now indicated to treat metastatic castration-sensitive prostate cancer (mCSPC).
July 26, 2019

FDA Issues Safety Communication for Xeljanz

July 26, 2019 – The U.S. FDA has issued a safety communication cautioning that Xeljanz® (tofacitinib) and Xeljanz XR® (tofacitinib), manufactured by Pfizer, may increase the risk of blood clots and death when taken at higher doses.
July 25, 2019

Accrufer Approved to Treat Iron Deficiency

July 25, 2019 – The U.S. FDA has approved AccruferTM (ferric maltol), manufactured by Shield Therapeutics, to treat iron deficiency in adults. The product is a new means of treating iron deficiency compared
12345678910111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182838485868788899091